2018: NIH licenses on Anti-Mesothelin CAR to Atara Biotherapeutics

Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics Inc.


The eight groups signing the comments were:

  • Health Action International (HAI)
  • Health GAP
  • Interfaith Center on Corporate Responsibility (ICCR)
  • Knowledge Ecology International (KEI)
  • People of Faith for Access to Medicines (PFAM)
  • Social Security Works (SSW)
  • Union for Affordable Cancer Treatment (UACT)
  • Universities Allied for Essential Medicines (UAEM)